Eyewire Today

Advertisement

Mood, Cognitive Ability, and Sleep Patterns in Patients With Alzheimer Disease Improved After Cataract Surgery

From EyewireToday.com

Patients with mild Alzheimer disease whose vision improved after cataract surgery also experienced improvements in cognitive ability, mood, sleep patterns, and other behaviors, according to a study presented by Brigitte Girard, MD, at the AAO annual meeting in Orlando.[1] The results were also reported in an AAO news release.The study, conducted by...

Login to read story

Monday, September 29, 2014

Show last days of articles

Nicox Glaucoma Drug Effective in Late-Stage Studies

From Medscape Ophthalmology — 9/29/2014

French pharmaceutical firm Nicox unveiled positive topline Phase 3 results for its glaucoma drug on Thursday and said, if approved by regulators, the ...Full story

Alimera Sciences Provides Details on FDA Approval of Iluvien...

From Alimera Sciences — 9/29/2014

Alimera Sciences announced that it will hold a conference call to provide additional information regarding the recent approval by the FDA of Iluvien f...Full story

Scientists are Developing Eye Drops to Treat Molecular Basis...

From Medical News Today — 9/29/2014

Northwestern Medicine scientists have discovered a novel cause of glaucoma in an animal model, and related to their findings, are now developing an ey...Full story

Friday, September 26, 2014

Alimera Sciences Receives FDA Approval For Iluvien, The Firs...

From Eyewiretoday.com — 9/26/2014

Alimera Sciences announced that the FDA has approved Iluvien for the treatment of diabetic macular edema (DME) in patients who have been previously tr...Full story

Immediate Sequential Cataract Surgery Reduces Ophthalmologis...

From Medscape Ophthalmology — 9/26/2014

Lower current reimbursement rates for immediate sequential cataract surgery (ISCS) compared with delayed sequential cataract surgery (DSCS) result in ...Full story

Bausch + Lomb Announces Results from Phase 3 Study of Sub-Mi...

From Bausch + Lomb — 9/26/2014

Bausch + Lomb announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle ge...Full story

UK Eye Health Companies Form Industry Vision Group to Improv...

From Medical News Today — 9/26/2014

A number of companies have joined together to form the Industry Vision Group (IVG), which brings together pharmaceutical and medical technology compan...Full story

Brain Mechanism Underlying the Recognition of Hand Gestures ...

From Medical News Today — 9/26/2014

Does a distinctive mechanism work in the brain of congenitally blind individuals when understanding and learning others' gestures? Or does the same me...Full story

Thursday, September 25, 2014

James Mazzo, Ex-Advanced Medical Optics CEO, Indicted in Ins...

From Bloomberg — 9/25/2014

Former Advanced Medical Optics Inc. Chief Executive Officer James Mazzo was charged with tipping a former Baltimore Orioles third baseman that his com...Full story

Ophthalmic Women Leaders to Host Industry Events at AAO

From Ophthalmic Women Leaders — 9/25/2014

Ophthalmic Women Leaders (OWL) announced that it will be attending and hosting several events at the 2014 American Academy of Ophthalmology meeting in...Full story

NAD Recommends Alcon Discontinue Certain Claims for Air Opti...

From National Advertising Division — 9/25/2014

The National Advertising Division (NAD) has recommended that Alcon Laboratories discontinue certain comparative superiority claims for the company's A...Full story

Lions Eye Institute for Transplant & Research Appoints New C...

From Lions Eye Institute for Transplant & ... — 9/25/2014

The Lions Eye Institute for Transplant & Research (LEITR) board of directors has elected John T. LiVecchi, MD, FACS, FSEE, a board-certified ophth...Full story

How a Single, Genetic Change Causes Retinal Tumors in Young ...

From Children's Hospital Los Angeles — 9/25/2014

Retinoblastoma is a childhood retinal tumor usually affecting children 1 to 2 years of age. Although rare, it is the most common malignant tumor of th...Full story

Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO (latanop...

From Bausch + Lomb — 9/25/2014

Bausch + Lomb and Nicox announced positive top-line results from the phase 3 studies conducted with VESNEO (latanoprostene bunod; previously known as ...Full story

Digital Tools Unveiled to Improve Doctor-Patient Interaction

From Medscape Ophthalmology — 9/25/2014

Software programs can encourage communication between doctors and patients, reducing costs and improving outcomes, Silicon Valley entrepreneurs say. "...Full story

Wednesday, September 24, 2014

Genzyme Collaborates on Gene Therapy for Rare Disease that C...

From Genzyme — 9/24/2014

Genzyme announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene th...Full story

Novaliq GmbH Reports Positive Results from CyclASol (Cyclosp...

From Novaliq GmbH — 9/24/2014

Novaliq GmbH reported positive phase 1 results with the first and only clear cyclosporin solution eye drop formulation in clinical development for pat...Full story

Pfizer Said to Approach Actavis to Gauge Interest in Deal

From Bloomberg — 9/24/2014

Pfizer has approached Actavis Plc to express its interest in an acquisition, people with knowledge of the matter said, as the U.S. drugmaker continues...Full story

A Spontaneous Retinal Neovascular Mouse Model

From Medical News Today — 9/24/2014

Neovascular age-related macular degeneration (AMD), which involves formation of abnormal blood vessels in the retina, is a leading cause of vision los...Full story

Limit Ranibizumab Injections in Macular Degeneration

From Medscape Ophthalmology — 9/24/2014

The lucky number is 7 or 7.1 to be exact the mean optimum number of injections of intravitreal ranibizumab (Lucentis, Genentech) that should be give...Full story

Advertisement

Featured Jobs
  • Cornea Specialist

    MA (Statewide)

    Cornea Specialist, Massachusetts Multi-physician/multi-Subspecialty/multi-Location practice in central Massachusetts (just west of Boston) is seeking a board-certified/board-eligible cornea specialist to join their estab...

Featured Events